Adagene (FRA:978) Debt-to-Revenue : N/A (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Adagene Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Adagene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €14.97 Mil. Adagene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €4.34 Mil. Adagene's annualized Revenue for the quarter that ended in Jun. 2024 was €0.00 Mil.

Adagene Debt-to-Revenue Historical Data

The historical data trend for Adagene's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Debt-to-Revenue Chart

Adagene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

5.32

11.39

0.74

3.01

1.23

Adagene Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Revenue	Get a 7-Day Free Trial						2.17	2.61	0.73	13.67	N/A

Competitive Comparison of Adagene's Debt-to-Revenue

For the Biotechnology subindustry, Adagene's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Adagene's Debt-to-Revenue falls into.

Adagene Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Adagene's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(7.88	+	12.576)	/	16.608
	=	1.23

Adagene's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(14.972	+	4.342)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.

Adagene Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Adagene's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Adagene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ADAG:USA

Address

Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123

Website

https://www.adagene.com

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene Headlines

No Headlines